Neuropharma and JSW Research agree to co-develop transgenic mouse models focusing on GSK3â.

The mouse model represents an extremely valuable tool for the elucidation of the molecular basis of neurodegenerative diseases like AD for research companies working in CNS physiology and pathology

(PresseBox) ( Graz, )
Neuropharma, subsidiary of the Zeltia group specializing in the research and development of innovative drugs for the treatment of neurodegenerative disorders, announced that it has granted to JSW Research Ltd. a non-exclusive licence to produce, develop and market the Tet/GSK3â transgenic mouse and any future cross-bred mouse lines.

This mouse exhibits some of the features observed in Alzheimer’s disease and represents an extremely valuable tool for the elucidation of the molecular basis of neurodegenerative diseases for research companies working in CNS physiology and pathology.

Neuropharma owns the exclusive rights to the Tet/GSK3â transgenic mouse model and has used it in the development of NP12, its novel GSK3 inhibitor against Alzheimer currently in phase I clinical trials, as well as in other GSK3 inhibitors in its pipeline.

JSW Research Ltd., based in Graz, Austria, is a contract research organization that offers comprehensive research and consulting programs for drug development for CNS disorders. The company has exclusive neurodegeneration models and transgenic animal models focused on this therapeutic area. With access to this Tet GSK3 mouse JSW Research Ltd. will complete the range of models available for pharmacological research in neurodegenerative diseases.

Dr. Belén Sopesen, Managing Director of Neuropharma, commented: “We are very pleased to work with JSW Research Ltd., a leader in Europe in neurodegeneration and transgenic animal models. This license opens the door to further collaboration”.

Dr. Manfred Windisch, CEO of JSW, acknowledges the achievements of Neuropharma in the development of new treatments for neurodegenerative disesases: “JSW is proud having the chance to collaborate with one of the most innovative and successful drug development companies in Europe”.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an